USCOM LIMITED — Regulatory Filings 2009

Apr 22, 2009

==> picture [71 x 87] intentionally omitted <==

MARKET ANNOUNCEMENT

Uscom receives Frost & Sullivan Emerging Company of the Year Award

Thursday, 23 April 2009 Uscom Ltd (ASX code UCM) today announced that it had received the Frost & Sullivan award for the Medical Devices Emerging Company of the Year at the 2009 Asia Pacific Frost & Sullivan Excellence in Healthcare Awards.

Uscom is honoured to receive such a prestigious award and this strongly reflects the efforts by the entire Uscom team. This is in recognition of recent major milestones achieved by the company. Uscom managed to secure its strategic relationship with Spacelabs for distribution of Ultrasonic Cardiac Monitors in the Americas, Europe, Middle East, Africa and India late last year. Since the beginning of this year Uscom has received orders for 88 units, including 77 from Spacelabs. Additionally the USCOM technology became included in the new Sepsis Guidelines for Children. The USCOM technology was also published in the peer reviewed American Journal of Surgery in December 2008, in a land mark study from the world leading Los Angeles Cedar’s Sinai Hospital ICU. The publication titled “Non-Invasive Doppler ultrasonography for assessing cardiac function: can it replace the Swan-Ganz?’ concluded that “the device is a good substitute over the PAC for determining cardiac function and can be used by a wide range of ICU personnel”. This award reflects these achievements, as well as all of the effort put in throughout the organisation and the results achieved by the team. It also shows the market that Uscom is a growing company, ready and able to overcome the challenges that lie ahead.

The Frost & Sullivan Awards recognize the superior planning and execution of product launches, strategic alliances, distribution strategies, technological innovations, customer service, and mergers and acquisitions. A host of other crucial marketing factors such as leadership, strategy, service, innovation, integration, and development are also considered as part of the Award methodology. The Frost & Sullivan Best Practices Awards can be a boost for organizations not only because of the recognition they bring, but also in terms of industry standings.

Sohini Mitra the Research Manager for Asia Pacific Healthcare Practice said that "USCOM's latest product, OXYCOM, along with their flagship product the USCOM 1A offers a completely non-invasive approach to hemodynamics that enables early and accurate detection of circulatory dysfunction. This technological innovation has contributed significantly to the evolution of cardiac output measurement - from using invasive methods to a completely non-invasive method that is safer for patients.

==> picture [185 x 62] intentionally omitted <==

Uscom Limited Level 7, 8-10 Loftus Street Sydney NSW 2000 Australia Phone: 61-2-9247 4144 Fax: 61-2-9247 8157 ABN: 35 091 028 090

Testimony of the acceptance of this innovation is reflected in the company's geographic expansion in the Asia Pacific Region in the last 2 years and potential acceptance is demonstrated in Uscom establishing a distribution partnership to enter new markets and strengthen their presence in existing markets.

Uscom is recognized by this award for demonstrating technological innovation and leadership, which has enabled the company to participate and contribute significantly to its industry."

About Uscom

Uscom Limited is an Australian medical device company, listed on the Australian Stock Exchange since December 2003. Uscom has developed a device for the safe and accurate measurement of cardiac output, a non-invasive alternative to the current invasive methods. Uscom offers a completely safe, painless and quick method of accurately measuring how well the heart is pumping. With its real-time beat-to-beat information across multiple parameters of cardiac function and advanced serial measurement capabilities, clinicians can accurately quantify the impact of therapy. The device is ideally suited to the Emergency Care setting where it is critical to monitor changes in cardiac output as fluids are applied.

The Company has secured regulatory approval for sale of the Uscom Monitor in Australia, Europe and a number of Asian markets, including Japan, China and Taiwan. Uscom also has a CE Mark certification for Europe and a license from the State Food & Drug Administration for China. The Company received the necessary regulatory clearance for the United States market in February 2005 with the receipt of a 510K Pre Market Notification from the US Food & Drug Administration (FDA).

Uscom Contacts

Paul Butler Chief Executive Officer Office: +1 646 379 3278 paul.butler@uscom.com.au

Rob Phillips Executive Chairman Office: 02 9247 4144 rob@uscom.com.au

==> picture [185 x 62] intentionally omitted <==

Uscom Limited Level 7, 8-10 Loftus Street Sydney NSW 2000 Australia Phone: 61-2-9247 4144 Fax: 61-2-9247 8157 ABN: 35 091 028 090